Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Prostamax cycle length: what human studies ran

Not approved — research use onlyDMechanistic only
Short answer: there is no established Prostamax cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Prostamax combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Prostamax cycle length?
No. We found no human studies that report a treatment duration for Prostamax.
What is the longest human study of Prostamax?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Prostamax dosing reference Full research page

References

  1. [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ] Biofizika. 2004
  2. [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats] Adv Gerontol. 2006
  3. [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)] Georgian Med News. 2012
  4. Effects of short peptides on lymphocyte chromatin in senile subjects Bull Exp Biol Med. 2004
  5. Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax Georgian Med News. 2009
  6. Drugs@FDA: FDA-Approved Drugs (search of approved applications) FDA Drugs@FDA / openFDA drug/drugsfda. 2026
  7. DailyMed label search (structured product labels) NLM DailyMed. 2026
  8. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act, updated May 14, 2026 FDA. 2026
  9. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026